

8 Literatur

- 1 Dawber TR, Kannel WB. The Framingham study. An epidemiological approach to coronary heart disease. *Circulation* 1966;34:553-5.
- 2 Schildkraut JM, Myers RH, Cupples LA, Kiely DK, Kannel WB. Coronary risk associated with age and sex of parental heart disease in the Framingham Study. *Am J Cardiol* 1989;64:555-9
- 3 Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W, Peto R. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. *N Engl J Med* 1996;334:1145-9.
- 4 Buring JE, Hennekens CH, for the Women's Health Study Research Group. The Women's Health Study: summary of the study design. *J Myocardial Ischemia* 1992;4:27-29.
- 5 Douglas PS, Ginsburg GS. The evaluation of chest pain in women. *N Engl J Med* 1996;334:1311-5.
- 6 Sesso HD, Lee IM, Gaziano JM, Rexrode KM, Glynn RJ, Buring JE. Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women. *Circulation* 2001;104:393-8.
- 7 Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. *N Engl J Med* 1994; 330:1041-6.
- 8 Andresdottir MB, Sigurdsson G, Sigvaldason H, Gudnason V; Reykjavik Cohort Study. Fifteen percent of myocardial infarctions and coronary revascularizations explained by family history unrelated to conventional risk factors. *The Reykjavik Cohort Study. Eur Heart J* 2002;23:1655-63.
- 9 Hengstenberg C, Brockel U, Holmer S, Mayer B, Fischer M, Baessler A, Erdmann J, Lieb W, Lowel H, Riegger G, Schunkert H Genetic factors in myocardial infarction--Results from a candidate gene and a genome-wide approach between beta blockers. *Herz* 2002;27:649-61.
- 10 Winkelmann BR, Hager J, Kraus WE, Merlini P, Keavney B, Grant PJ, Muhlestein JB, Granger CB. Genetics of coronary heart disease: current knowledge and research principles. *Am Heart J* 2000;140:S11-26.
- 11 Sham PC, Cherny SS, Purcell S, Hewitt JK. Power of linkage versus association analysis of quantitative traits, by use of variance-components models, for sibship data. *Am J Hum Genet* 2000;66:1616-30.

- 12 Breslow NE, Day NE. Statistical methods in cancer research: Vol. 1, The analysis of case-control-studies. Intern. Agency for Research on Cancer. Lyon, France. 1980.
- 13 Nagel M, Wernecke KD, Fleischer W. Computergestützte Datenanalyse. Verlag Technik. Berlin, München. 1994.
- 14 Fleiss JL. Statistical methods for rates and proportions. John Wiley & Sons. New York. 1981.
- 15 Bock J, Toutenburg H. Sample size determination in clinical research. In: Rao CR, Chakraborty R (eds.) Handbook of Statistics, Vol. 8. Elsevier Publ. 1991.
- 16 Hintze L. PASS (NCSS series). Kaysville, Utah. 1991.
- 17 Hochberg Y, Tamhane AC. Multiple Comparison Procedures. John Wiley & Sons. New York. 1987.
- 18 Dupont W. Power calculations for matched case-control-studies. Biometrics 1988;44:1157-68.
- 19 Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999;340:115-26.
- 20 Gawaz M. Das Blutplättchen.: Physiologie, Pathophysiologie, Membranrezeptoren, antithrombozytäre Wirkstoffe und antithrombozytäre Therapie bei koronarer Herzerkrankung. Thieme. Stuttgart, New York. 1999.
- 21 Fredrickson BJ, Dong JF, McIntire LV, Lopez JA. Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. Blood 1998;92:3684-93.
- 22 Furihata K, Nugent DJ, Kunicki TJ. Influence of platelet collagen receptor polymorphisms on risk for arterial thrombosis. Arch Pathol Lab Med 2002;126:305-9.
- 23 Reiner AP, Siscovick DS, Rosendaal FR. Platelet glycoprotein gene polymorphisms and risk of thrombosis: facts and fancies. Rev Clin Exp Hematol 2001;5:262-87; discussion 311-2.
- 24 Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood. 1988;71:831-43.
- 25 Meisel C, Lopez JA, Stangl K. Role of platelet glycoprotein polymorphisms in cardiovascular diseases. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:38-54.
- 26 Crouch MA, Nappi JM, Cheang KI. Glycoprotein IIb/IIIa receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome. Ann Pharmacother. 2003;37:860-75.

- 27 Santoro SA. Platelet surface collagen receptor polymorphisms: variable receptor expression and thrombotic/hemorrhagic risk. *Blood* 1999;93:3575-7.
- 28 Kunicki TJ, Orzechowski R, Annis D, Honda Y. Variability of integrin alpha 2 beta 1 activity on human platelets. *Blood* 1993;82:2693-703.
- 29 Kritzik M, Savage B, Nugent DJ, Santoso S, Ruggeri ZM, Kunicki TJ. Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated with differences in platelet alpha2 beta1 density. *Blood* 1998;92:2382-8.
- 30 Kunicki TJ, Annis DS, Felding Habermann B. Molecular determinants of arg-gly-asp ligand specificity for beta3 integrins. *J Biol Chem* 1997;272:4103-7.
- 31 Reiner AP, Kumar PN, Schwartz SM, Longstreth WT Jr, Pearce RM, Rosendaal FR, Psaty BM, Siscovick DS. Genetic variants of platelet glycoprotein receptors and risk of stroke in young women. *Stroke* 2000;31:1628-33.
- 32 Roest M, Banga JD, Grobbee DE, de Groot PG, Sixma JJ, Tempelman MJ, van der Schouw YT. Homozygosity for 807 T polymorphism in alpha(2) subunit of platelet alpha(2)beta(1) is associated with increased risk of cardiovascular mortality in high-risk women. *Circulation* 2000;102:1645-50.
- 33 Santoso S, Kunicki TJ, Kroll H, Haberbosch W, Gardemann A. Association of the Platelet Glycoprotein Ia C807T Gene Polymorphism With Nonfatal Myocardial Infarction in Young Patients. *Blood* 1999;93:2449-2453.
- 34 Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. *Circulation* 2003;107:1117-22.
- 35 Lopez JA, Dong JF. Structure and function of the glycoprotein Ib-IX-V complex. *Curr Opin Hematol* 1997;4:323-9.
- 36 Ware J. Molecular analyses of the platelet glycoprotein Ib-IX-V receptor. *Thromb Haemost* 1998;79:466-78.
- 37 Lopez JA, Andrews RK, Afshar Kharghan V, Berndt MC. Bernard-Soulier syndrome. *Blood* 1998;91:4397-418.
- 38 Moroi M, Jung SM, Yoshida N. Genetic polymorphism of platelet glycoprotein Ib. *Blood* 1984;64:622-9.
- 39 Ishida F, Furihata K, Ishida K, Yan J, Kitano K, Kiyosawa K, Furuta S. The largest variant of platelet glycoprotein Ib alpha has four tandem repeats of 13 amino acids in the

- macroglycopeptide region and a genetic linkage with methionine145. *Blood* 1995;86:1357-60.
- 40 Kuijpers RW, Faber NM, Cuypers HT, Ouwehand WH, von dem Borne AE. NH2-terminal globular domain of human platelet glycoprotein Ib alpha has a methionine 145/threonine145 amino acid polymorphism, which is associated with the HPA-2 (Ko) alloantigens. *J Clin Invest* 1992;89:381-4.
- 41 Afshar Kharghan V, Li CQ, Khoshnevis Asl M, Lopez JA. Kozak sequence polymorphism of the glycoprotein (GP) Ibalpha gene is a major determinant of the plasma membrane levels of the platelet GP Ib-IX-V complex. *Blood* 1999;94:186-91.
- 42 Rapaport SI, Rao LV. Initiation and regulation of tissue factor-dependent blood coagulation. *Arterioscler Thromb* 1992;12:1111-21.
- 43 Nemerson Y. Tissue factor: then and now. *Thromb Haemost* 1995;74:180-4.
- 44 Rao LV, Rapaport SI. Cells and the activation of factor VII. *Haemostasis* 1996;26:1-5.
- 45 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. *Lancet* 1986;2:533-7.
- 46 Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. *Blood* 2000;95:1517-32.
- 47 Bernardi F, Marchetti G, Pinotti M, Arcieri P, Baroncini C, Papacchini M, Zeponi E, Ursicino N, Chiarotti F, Mariani G. Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. *Arterioscler Thromb Vasc Biol* 1996;16:72-6.
- 48 Hunault M, Arbini AA, Lopaciuk S, Carew JA, Bauer KA. The Arg353Gln polymorphism reduces the level of coagulation factor VII. In vivo and in vitro studies. *Arterioscler Thromb Vasc Biol* 1997;17:2825-9.
- 49 Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. *Circulation* 2001;104:2673-8.
- 50 Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? *Circulation* 2004;109(Suppl 1):II27-33.
- 51 Yokoyama M. Oxidant stress and atherosclerosis. *Curr Opin Pharmacol* 2004;4:110-5.
- 52 Nickenig G. Central role of the AT1-receptor in atherosclerosis. *J Hum Hypertens* 2002;16:26-33.

- 53 Bonnardeaux A, Davies E, Jeunemaitre X, Fery I, Charru A, Clauser E, Tiret L, Cambien F, Corvol P, Soubrier F. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. *Hypertension* 1994;24:63-9.
- 54 Buraczynska M, Ksiazek P, Zaluska W, Spasiewicz D, Nowicka T, Ksiazek A. Angiotensin II type 1 receptor gene polymorphism in end-stage renal disease. *Nephron* 2002;92:51-5.
- 55 Henskens LH, Spiering W, Stoffers HE, Soomers FL, Vlietinck RF, de Leeuw PW, Kroon AA. Effects of ACE I/D and AT1R-A1166C polymorphisms on blood pressure in a healthy normotensive primary care population: first results of the Hippocrates study. *J Hypertens* 2003;21:81-6.
- 56 Mettimano M, Romano-Spica V, Ianni A, Specchia M, Migneco A, Savi L. AGT and AT1R gene polymorphism in hypertensive heart disease. *Int J Clin Pract* 2002;56:574-7.
- 57 Reich H, Duncan JA, Weinstein J, Cattran DC, Scholey JW, Miller JA. Interactions between gender and the angiotensin type 1 receptor gene polymorphism. *Kidney Int* 2003;63:1443-9.
- 58 Gross SS, Wolin MS. Nitric oxide: pathophysiological mechanisms. *Annu Rev Physiol* 1995;57:737-769.
- 59 Albrecht EW, Stegeman CA, Heeringa P, Henning RH, van Goor H. Protective role of endothelial nitric oxide synthase. *J Pathol* 2003;199:8-17.
- 60 Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. *Annu Rev Physiol* 2002;64:749-74.
- 61 Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. *J Am Coll Cardiol* 2004;43:1731-7.
- 62 Barbato JE, Tzeng E. Nitric oxide and arterial disease. *J Vasc Surg* 2004;40:187-93.
- 63 Shaul PW. Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis. *J Physiol* 2003;547:21-33.
- 64 Chen J, Kuhlencordt PJ, Astern J, Gyurko R, Huang PL. Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitric oxide synthase double knockout mice. *Circulation* 2001;104:2391-4.
- 65 Wang XL, Wang J. Endothelial nitric oxide synthase gene sequence variations and vascular disease. *Mol Genet Metab* 2000;70:241-51.
- 66 Austin RC, Lentz SR, Werstuck GH. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. *Cell Death Differ* 2004;11 Suppl 1:S56-64.

- 67 Mayer O Jr, Simon J, Rosolova H, Hromadka M, Subrt I, Vobrubova I. The effects of folate supplementation on some coagulation parameters and oxidative status surrogates. *Eur J Clin Pharmacol* 2002;58:1-5.
- 68 Sauls DL, Wolberg AS, Hoffman M. Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. *J Thromb Haemost* 2003;1:300-6.
- 69 Mangoni AA, Jackson SH. Homocysteine and cardiovascular disease: current evidence and future prospects. *Am J Med* 2002;112:556-65.
- 70 Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. *Am J Hum Genet* 1988;43:414-21.
- 71 Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. *Nat Genet* 1995;10:111-3.
- 72 Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. *Circulation* 1996;93:7-9.
- 73 Nakai K, Itoh C, Nakai K, Habano W, Gurwitz D. Correlation between C677T MTHFR gene polymorphism, plasma homocysteine levels and the incidence of CAD. *Am J Cardiovasc Drugs* 2001;1:353-61.
- 74 van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, van den Heuvel LP, Blom HJ. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? *Am J Hum Genet* 1998;62:1044-51.
- 75 Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. *Mol Genet Metab* 1998;64:169-72.
- 76 Dzimiri N. Receptor crosstalk. Implications for cardiovascular function, disease and therapy. *Eur J Biochem* 2002;269:4713-30.
- 77 Wenzel RR, Siffert W, Bruck H, Philipp T, Schafers RF. Enhanced vasoconstriction to endothelin-1, angiotensin II and noradrenaline in carriers of the GNB3 825T allele in the skin microcirculation. *Pharmacogenetics* 2002;12:489-95.

- 78 Koch WJ, Hawes BE, Allen LF, Lefkowitz RJ. Direct evidence that Gi-coupled receptor stimulation of mitogen-activated protein kinase is mediated by G beta gamma activation of p21ras. *Proc Natl Acad Sci U S A* 1994;91:12706-10.
- 79 Davies MG, Huynh TT, Fulton GJ, Lefkowitz RJ, Svendsen E, Hagen PO, Koch WJ. G protein signaling and vein graft intimal hyperplasia: reduction of intimal hyperplasia in vein grafts by a Gbetagamma inhibitor suggests a major role of G protein signaling in lesion development. *Arterioscler Thromb Vasc Biol* 1998;18:1275-80.
- 80 Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. *Proc Natl Acad Sci U S A* 1998;95:8070-4.
- 81 Siffert W. Molecular genetics of G proteins and atherosclerosis risk. *Basic Res Cardiol* 2001;96:606-11.
- 82 Wenzel RR, Siffert W, Bruck H, Philipp T, Schäfers RF. Enhanced vasoconstriction to endothelin-1, angiotensin II and noradrenaline in carriers of the GNB3 825T allele in the skin microcirculation. *Pharmacogenetics* 2002;12:489-95.
- 83 Siffert W, Roskopf D, Siffert G, Busch S, Moritz A, Erbel R, Sharma AM, Ritz E, Wichmann HE, Jakobs KH, Horsthemke B. Association of a human G-protein beta3 subunit variant with hypertension. *Nat Genet* 1998;18:45-8.
- 84 Jacobi J, Hilgers KF, Schlaich MP, Siffert W, Schmieder RE. 825T allele of the G-protein beta3 subunit gene (GNB3) is associated with impaired left ventricular diastolic filling in essential hypertension. *J Hypertens* 1999;17:1457-62.
- 85 Hamilton CA, Miller WH, Al-Benna S, Brosnan MJ, Drummond RD, McBride MW, Dominiczak AF. Strategies to reduce oxidative stress in cardiovascular disease. *Clin Sci (Lond)* 2004;106:219-34.
- 86 Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. *Atherosclerosis* 2004;173:1-12.
- 87 Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Eroglu J, Hsu C, Dunlop C, La Du B. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. *Arterioscler Thromb Vasc Biol* 1998;18:1617-24.
- 88 Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. *Nature* 1998;394:284-7.

- 89 Draganov DI, La Du BN. Pharmacogenetics of paraoxonases: a brief review. *Naunyn Schmiedebergs Arch Pharmacol* 2004;369:78-88.
- 90 Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. *Arterioscler Thromb Vasc Biol* 2001;21:473-80.
- 91 Strosberg AD. Association of beta 3-adrenoceptor polymorphism with obesity and diabetes: current status. *Trends Pharmacol Sci* 1997;18:449-54.
- 92 Leineweber K, Buscher R, Bruck H, Brodde OE. Beta-adrenoceptor polymorphisms. *Naunyn Schmiedebergs Arch Pharmacol* 2004;369:1-22.
- 93 Canello R, Tounian A, Poitou Ch, Clement K. Adiposity signals, genetic and body weight regulation in humans. *Diabetes Metab* 2004;30:215-27.
- 94 Meier U, Gressner AM. Endocrine Regulation of Energy Metabolism: Review of Pathobiochemical and Clinical Chemical Aspects of Leptin, Ghrelin, Adiponectin, and Resistin. *Clin Chem* 2004;Jul 20 [Epub ahead of print].
- 95 Rahmouni K, Haynes WG. Leptin and the cardiovascular system. *Recent Prog Horm Res* 2004;59:225-44.
- 96 Correia ML, Haynes WG. Leptin, obesity and cardiovascular disease. *Curr Opin Nephrol Hypertens* 2004;13:215-23.
- 97 Loscalzo J. Functional polymorphisms in a candidate gene for atherothrombosis: unraveling the complex fabric of a polygenic phenotype. *J Am Coll Cardiol* 2003;41:946-8.
- 98 Grant PJ. The genetics of atherothrombotic disorders: a clinician's view. *J Thromb Haemost* 2003;1:1381-90.
- 99 Novelli G, Borgiani P, Giardina E, Mango R, Contino G, Romeo F, Mehta JL. Role of genetics in prevention of coronary atherosclerosis. *Curr Opin Cardiol* 2003;18:368-71.
- 100 Scheuner MT. Genetic evaluation for coronary artery disease. *Genet Med* 2003;5:269-85.
- 101 Daly AK. Candidate gene case-control studies. *Pharmacogenomics* 2003;4:127-39.
- 102 Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. *Lancet* 2003;361:865-72.
- 103 Tabor HK, Risch NJ, Myers RM. Opinion: Candidate-gene approaches for studying complex genetic traits: practical considerations. *Nat Rev Genet* 2002;3:391-7.
- 104 Kandzari DE, Goldschmidt-Clermont PJ. Platelet polymorphisms and ischemic heart disease: moving beyond traditional risk factors. *J Am Coll Cardiol* 2001;38:1028-32.

- 105 Zhu MM, Weedon J, Clark LT. Meta-analysis of the association of platelet glycoprotein IIIa PIA1/A2 polymorphism with myocardial infarction. *Am J Cardiol* 2000;86:1000-4.
- 106 Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Platelet glycoprotein receptor IIIa polymorphism PIA1/A2 and coronary risk: a meta-analysis. *Thromb Haemost* 2001;85:626-33.
- 107 von Beckerath N, Koch W, Mehilli J, Böttinger C, Schömig A, Kastrati A. Glycoprotein Ia C807T polymorphism and risk of restenosis following coronary stenting. *Atherosclerosis* 2001;156:463-8.
- 108 Santoso S, Zimmermann P, Sachs UJ, Gardemann A. The impact of the Kozak sequence polymorphism of the glycoprotein Ib alpha gene on the risk and extent of coronary heart disease. *Thromb Haemost* 2002;87:345-6.
- 109 Corral J, Lozano ML, Gonzalez-Conejero R, Martinez C, Iniesta JA, Rivera J, Vicente V. A common polymorphism flanking the ATG initiator codon of GPIb alpha does not affect expression and is not a major risk factor for arterial thrombosis. *Thromb Haemost* 2000;83:23-8.
- 110 Ishida F, Ito T, Takei M, Shimodaira S, Kitano K, Kiyosawa K. Genetic linkage of Kozak sequence polymorphism of the platelet glycoprotein Ib alpha with human platelet antigen-2 and variable number of tandem repeats polymorphism, and its relationship with coronary artery disease. *Br J Haematol* 2000;111:1247-9.
- 111 Kenny D, Muckian C, Fitzgerald DJ, Cannon CP, Shields DC. Platelet glycoprotein Ib alpha receptor polymorphisms and recurrent ischemic events in acute coronary syndrome patients. *J Thromb Thrombolysis* 2002;13:13-9.
- 112 Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. *Arterioscler Thromb* 1991;11:540-6.
- 113 Heywood DM, Ossei-Gerning N, Grant PJ. Association of factor VII:C levels with environmental and genetic factors in patients with ischaemic heart disease and coronary atheroma characterised by angiography. *Thromb Haemost* 1996;76:161-5.
- 114 Endler G, Mannhalter C. Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis. *Clin Chimica Acta* 2003;330:31-55.
- 115 Feng D, Tofler GH, Larson MG, O'Donnell CJ, Lipinska I, Schmitz C, Sutherland PA, Johnstone MT, Muller JE, D'Agostino RB, Levy D, Lindpaintner K. Factor VII gene polymorphism, factor VII levels, and prevalent cardiovascular disease: the Framingham Heart Study. *Arterioscler Thromb Vasc Biol* 2000;20:593-600.

- 116 Lane A, Green F, Scarabin PY, Nicaud V, Bara L, Humphries S, Evans A, Luc G, Cambou JP, Arveiler D, Cambien F. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. *Atherosclerosis* 1996;119:119-27.
- 117 Danser AH, Schunkert H. Renin-angiotensin system gene polymorphisms: potential mechanisms for their association with cardiovascular diseases. *Eur J Pharm* 2000;410:303-16.
- 118 Miller JA, Scholey JW. The impact of renin-angiotensin system polymorphisms on physiological and pathophysiological processes in humans. *Curr Opin Nephrol Hypertens* 2004;13:101-6.
- 119 Casas JP, Bautista LE, Humphries SE, Hingorani AD. Endothelial nitric oxide synthase genotype and ischemic heart disease – meta-analysis of 26 studies involving 23028 subjects. *Circulation* 2004;109:1359-65.
- 120 Nakayama T, Soma M, Takahashi Y, Izumi Y, Kanmatsuse K, Esumi M. Association analysis of CA repeat polymorphism of the endothelial nitric oxide synthase gene with essential hypertension in Japanese. *Clin Genet* 1997;51:26-30.
- 121 Hui J, Stangl K, Lane WS, Bindereif A. HnRNP L stimulates splicing of the eNOS gene by binding to variable-length CA repeats. *Nat Struct Biol* 2003;10:33-7.
- 122 Yokoyama M. Oxidant stress and atherosclerosis. *Curr Opin Pharmacol* 2004;4:110-5.
- 123 Verhoef P. Hyperhomocysteinemia and risk of vascular disease in women. *Semin Thromb Hemost* 2000;26:325-34.
- 124 Klerk M; Verhoef P; Clarke R; Blom HJ; Kok FJ; Schouten EG; and the MTHFR Studies Collaboration Group. MTHFR 677C→T Polymorphism and Risk of Coronary Heart Disease: A Meta-analysis. *Jama* 2002;288:2023-31.
- 125 Currie IC, Wilson YG, Scott J, Day A, Stansbie D, Baird RN, Lamont PM, Tennant WG. Homocysteine: an independent risk factor for the failure of vascular intervention. *Br J Surg* 1996;83:1238-41.
- 126 Schnyder G, Flammer Y, Roffi M, Pin R, Hess OM. Plasma homocysteine levels and late outcome after coronary angioplasty. *J Am Coll Cardiol* 2002;40:1769-76.
- 127 von Beckerath N, Kastrati A, Koch W, Bottiger C, Mehilli J, Seyfarth M, Schomig A. G protein beta3 subunit polymorphism and risk of thrombosis and restenosis following coronary stent placement. *Atherosclerosis* 2000;149:151-5.

- 128 Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. *Lancet* 2004;363:689-95.
- 129 Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). *Circulation* 2001;104:3052-6.
- 130 Mooser V, Waterworth DM, Isenhour T, Middleton L. Cardiovascular pharmacogenetics in the SNP era. *J Thromb Haemost* 2003;1:1398-402.
- 131 Cardon LR, Abecasis GR. Using haplotype blocks to map human complex trait loci. *Trends Genet* 2003;19:135-40.
- 132 de Bakker PI, Saxena R, Graham RR. Variation in the human genome and risk to common disease. Keystone Symposium on 'Human Genome Sequence Variation and the Inherited Basis of Common Diseases'. January 8-13, Breckenridge, Colorado, USA. *Pharmacogenomics* 2004;5:157-61.
- 133 Hauser ER, Crossman DC, Granger CB, Haines JL, Jones CJ, Mooser V, McAdam B, Winkelmann BR, Wiseman AH, Muhlestein JB, Bartel AG, Dennis CA, Dowdy E, Estabrooks S, Eggleston K, Francis S, Roche K, Clevenger PW, Huang L, Pedersen B, Shah S, Schmidt S, Haynes C, West S, Asper D, Booze M, Sharma S, Sundseth S, Middleton L, Roses AD, Hauser MA, Vance JM, Pericak-Vance MA, Kraus WE. A Genomewide Scan for Early-Onset Coronary Artery Disease in 438 Families: The GENE CARD Study. *Am J Hum Genet* 2004;75:436-47.
- 134 Schmith VD, Campbell DA, Sehgal S, Anderson WH, Burns DK, Middleton LT, Roses AD. Pharmacogenetics and disease genetics of complex diseases. *Cell Mol Life Sci* 2003;60:1636-46.